CLOuDs Disperse — Top-Notch Glucose Control and Residual C-Peptide Secretion

This editorial discusses the findings of the CLOuD trial, which investigated whether hybrid closed loop insulin therapy could preserve residual C peptide secretion in youths with new onset type 1 diabetes. Despite superior glycemic control in the closed loop group (lower HbA1c and more time in target range), no significant preservation of C peptide was observed. The author highlights the clinical benefits of residual C peptide secretion and suggests that future advancements in closed loop systems may offer better outcomes. The editorial underscores the importance of early intensive glucose control, even if beta cell decline remains unaltered.

This editorial discusses the findings of the CLOuD trial, which investigated whether hybrid closed loop insulin therapy could preserve residual C peptide secretion in youths with new onset type 1 diabetes. Despite superior glycemic control in the closed loop group (lower HbA1c and more time in target range), no significant preservation of C peptide was observed. The author highlights the clinical benefits of residual C peptide secretion and suggests that future advancements in closed loop systems may offer better outcomes. The editorial underscores the importance of early intensive glucose control, even if beta cell decline remains unaltered.